lobbying_activities: 2998857

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
2998857	93f06a6f-4f89-4219-9538-90044c2a2108	Q2	EMERGENT STRATEGIES	401104778	GENBIOPRO, INC.	2023	second_quarter	PHA	FDA Approval of generic mifepristone and related Risk Evaluation Mitigation Strategies (REMS).	HOUSE OF REPRESENTATIVES,SENATE	35000		0	0	2023-07-05T10:32:58-04:00